Latest News

09.01.2020

新型コロナウイルス・ワクチンEXG-5003の第 1/2 相臨床試験について

09.01.2020

Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University

11.19.2019

Elixirgen Therapeutics, Inc. raises $5 million in Series B round

07.09.2018

Elixirgen Therapeutics, Inc. raises $4 million in Series A funds

07.13.2012

Elixirgen awarded Investigator-Initiated Grant from MSCRF